Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.83 |
| ▸ | EP300 | Q09472 | 3/20 | 0.80 |
| ▸ | CHAT | P28329 | 2/20 | 0.80 |
| ▸ | AURKA | O14965 | 2/20 | 0.80 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.80 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.80 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2506879 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL1333343 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL31475488 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL2317294 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL380634 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL25273107 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL1332729 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL11026148 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL2510648 | 1.00 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL30558687 | 0.99 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12123045-B2 | Genetically modified cells that produce C6-C10 fatty acid derivatives | CARGILL, INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220403425-A1 | GENETICALLY MODIFIED CELLS THAT PRODUCE C6-C10 FATTY ACID DERIVATIVES | CARGILL, INCORPORATED (US) | 2022-12-22 | — | — | US | disclosed |
| US-11345938-B2 | Genetically modified cells that produce C6-C10 fatty acid derivatives | CARGILL, INCORPORATED (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2018144701-A2 | GENETICALLY MODIFIED CELLS THAT PRODUCE C6-C10 FATTY ACID DERIVATIVES | CARGILL INCORPORATED (US) | 2018-08-09 | — | — | WO | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-20120191434-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR MODELING CHINESE HAMSTER OVARY (CHO) CELL METABOLISM | GT LIFE SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2408927-A1 | PROBE COMPOUND FOR DETECTING AND ISOLATING ENZYMES AND MEANS AND METHODS USING THE SAME | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010105851-A1 | PROBE COMPOUND FOR DETECTING AND ISOLATING ENZYMES AND MEANS AND METHODS USING THE SAME | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-23 | — | — | WO | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100143940-A1 | (3R)-HYDROXYACYL-ACP DEHYDRATASE ENZYMES USED IN THE BIOSYNTHESIS OF MYCOLIC ACIDS AND USE OF SAME FOR SCREENING ANTIBIOTICS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143940-A1 | (3R)-HYDROXYACYL-ACP DEHYDRATASE ENZYMES USED IN THE BIOSYNTHESIS OF MYCOLIC ACIDS AND USE OF SAME FOR SCREENING ANTIBIOTICS | COASY, RIMKLA, HAGH | NAA50 228/4885EP300 1287/4885CHAT 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.